GlassScriptPhysician profile
Brian Vincent Viviano
NPI 1497984512
$45,941.84
in general payments reported to CMS, 2019-2025
35 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,061 · 2020: $2,533 · 2021: $4,898 · 2022: $2,264 · 2023: $2,586 · 2024: $15K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $8,951 · Travel and Lodging: $136 · Education: $29.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,070.00 |
| Food and Beverage | $8,950.59 |
| Travel and Lodging | $135.74 |
| Education | $29.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21,679.08 | 2024-2025 | Voquezna |
| Abbvie INC. | $8,536.31 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Allergan, INC. | $4,526.81 | 2019 | |
| Janssen Biotech, INC. | $2,256.54 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $1,606.67 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,265.27 | 2019-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $1,176.41 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $805.37 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $500.61 | 2019-2025 | Livdelzi |
| Novo Nordisk INC | $468.29 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Celgene Corporation | $464.81 | 2021-2024 | Zeposia |
| Amgen INC. | $429.39 | 2020-2023 | Avsola, Amjevita |
| Ironwood Pharmaceuticals, INC | $356.62 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $295.80 | 2020-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $209.86 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $207.65 | 2019-2025 | Tremfya |
| Madrigal Pharmaceuticals | $162.81 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $126.06 | 2020-2023 | Sutab |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2021 | |
| Vivus LLC | $96.37 | 2020-2025 | Qsymia |
| Redhill Biopharma INC. | $93.20 | 2020-2022 | |
| Lilly USA, LLC | $87.97 | 2023-2025 | Omvoh, Jardiance |
| Nestle Healthcare Nutrition INC. | $67.95 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $66.73 | 2019-2023 | Xarelto |
| Ardelyx, INC. | $65.84 | 2022-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $54.05 | 2025 | Zenpep |
| Celltrion USA INC. | $39.92 | 2024-2025 | Vegzelma, Zymfentra |
| Axonics, INC. | $30.07 | 2022 | |
| Alfasigma USA, INC. | $27.24 | 2020 | |
| Qol Medical, LLC | $21.68 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $20.63 | 2025 | Dupixent |
| Medtronic, INC. | $18.63 | 2025 | Interstim |
| Merck Sharp & Dohme LLC | $17.98 | 2021 | |
| Lifenet Health | $17.51 | 2025 | Theragenesis Wound Matrix |
| Bayer Healthcare Pharmaceuticals INC. | $16.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Viviano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.